VT-101
AXP000061.1 · Oncolytic virus
- Platform
- adenovirus
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Names
| Name | Type | Source |
|---|---|---|
| VT-101 ambiguous | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus (serotype not reported)
- Replication
- conditionally replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07905677 | Phase 1 Study of VT-101 in Advanced Ovarian Cancer | Recruiting | Phase 1 | 2026-10-26 | 2029-10-23 | 22 | Epithelial Ovarian Cancer; Ovarian Cancer |
| NCT06632964 | A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer | Unknown | Phase 1 | 2024-09-18 | 2025-09-01 | 16 | Non-muscle Invasive Bladder Cancer |
Recent changes
| Seen | Trial | Change | Detail | Title |
|---|---|---|---|---|
| 2026-11-12 | NCT07905677 | new trial | Phase 1 Study of VT-101 in Advanced Ovarian Cancer |
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39035212 | Cancer incidence and mortality in China, 2016. | Journal of the National Cancer Center | 2022 | cited by trial NCT06632964 |
| PMID 33924556 | Oncolytic Virotherapy for Cancer: Clinical Experience. | Biomedicines | 2021 | cited by trial NCT06632964 |
| PMID 32615118 | Cancer registration in China and its role in cancer prevention and control. | The Lancet. Oncology | 2020 | cited by trial NCT06632964 |
| PMID 28755959 | An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Urologic oncology | 2018 | cited by trial NCT06632964 |
| PMID 28981385 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018 | cited by trial NCT06632964 |
| PMID 28712033 | Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. | Cancer immunology, immunotherapy : CII | 2017 | cited by trial NCT06632964 |
| PMID 28886381 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. | Cell | 2017 | cited by trial NCT06632964 |
| PMID 26014293 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2015 | cited by trial NCT06632964 |
| PMID 23088985 | A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. | The Journal of urology | 2012 | cited by trial NCT06632964 |
Notes
Recombinant oncolytic adenovirus injection, NCT06632964. Construct not described in the registration.
How to cite
VT-101 (AXP000061.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000061.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.